Presentations on PARP Inhibition and Ovarian Cancer - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on PARP Inhibition and Ovarian Cancer

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Not a member of My prIME? Join now for instant access.

Enhance your understanding of the use of PARP inhibitors in ovarian cancer with downloadable slides from our satellite symposium. A variety of topics will be discussed, including DNA repair and PARP inhibition, use of PARP inhibitors in various settings, future directions, and practical considerations for PARP inhibitor therapy in the clinic.

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Nov 8, 2017

Expiration Date

Nov 8, 2018

Featured Expert

  • Thomas Helleday, PhD, Karolinska Institute, Stockholm, Sweden

Featured Topic

Everything a clinician needs to know about DNA repair and PARP inhibition

Featured Expert

  • Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, Arizona, United States

Featured Topic

A new string to the bow in the treatment of advanced ovarian cancer

Featured Expert

  • Rebecca Kristeleit, MD, PhD, UCL Cancer Institute, University College London, London, United Kingdom

Featured Topic

Clinical application of PARP inhibitors: Proactive management of adverse events

Featured Expert

  • Nicoletta Colombo, MD, PhD, University of Milan–Bicocca, European Institute of Oncology, Milan, Italy

Featured Topic

prIME Points™

This live educational activity is designed for oncologists, gynecologists, and other healthcare professionals interested and/or involved in the use of PARP inhibitors for the treatment of patients with ovarian cancer.

Upon completion of this educational activity, participants should be able to:

  • Describe current and emerging biomarkers that assess genomic instability and evaluate defects in DNA repair
  • Evaluate emerging clinical data and ongoing trials involving PARP inhibition for patients with BRCA 1/2 mutant and wildtype ovarian cancer
  • Assess the adverse events associated with PARP inhibition for ovarian cancer and how best to ensure long-term adherence to PARP inhibitors

This educational activity is supported by a grant from Clovis Oncology, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Colombo has disclosed that she has received consulting fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer Inc, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Helleday is chairman of the Helleday Foundation that is sponsoring clinical trials with DNA repair inhibitors, and he holds intellectual property rights He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kristeleit has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Monk has disclosed that he has performed contracted research for Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Morphotek, and Tesaro. He has also received consulting fees from Advaxis, Amgen, AstraZeneca, Bayer, Clovis, Gradalis, Insys, Mateon, Merck, Pfizer, PPD, Roche/Genentech, and Tesaro. He has also received fees for non-CME services received directly from commercial interest or their agents from AstraZeneca, Janssen/Johnson & Johnson, Myriad, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research for Amgen and Bayer
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.